VCYT
Healthcare Diagnostics & ResearchVeracyte, Inc.
$45.81
+1.08 +2.41% today
Price History
Not enough data
Key Stats
Market Cap
3.68B
Avg Volume
1.34M
P/E (TTM)
32.72
EPS
$1.40
52W High
$60.91
52W Low
$29.46
Div. Yield
0.0%
Analyst Ratings
Buy2
Str Buy
9
Buy
1
Hold
1
Sell
0
Str Sell
Valuation
Forward P/E
23.48
P/B Ratio
2.65
P/S Ratio
6.55
EV/EBITDA
28.52
EV/Revenue
5.76
Margins
Gross Margin 73.8%
Operating Margin 15.3%
Net Margin 20.4%
EBITDA Margin 20.2%
Growth & Returns
Revenue Growth (YoY)
15.5%
Return on Equity
8.8%
Return on Assets
4.1%
Liquidity & Leverage
Current Ratio
9.16
Quick Ratio
8.60
Debt / Equity
0.03
Total Cash
485.23M
Total Debt
40.11M
About
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
www.veracyte.com